BioCentury
ARTICLE | Distillery Therapeutics

Therapeutics: Fumarate hydratase (FH); v-abl Abelson murine leukemia viral oncogene homolog 1 (ABL1)

January 15, 2015 8:00 AM UTC

Cell culture and mouse studies suggest ABL1 inhibitors could help treat FH-deficient renal cancers. In FH-deficient hereditary leiomyomatosis and renal cell carcinoma (HLRCC) cell cultures, the ABL1 inhibitor vandetanib or an siRNA targeting ABL1 decreased glucose uptake and decreased colony formation compared with vehicle or siRNA control, respectively. In mice with FH-deficient HLRCC xenografts, vandetanib decreased tumor volume compared with vehicle. Next steps could include testing the effects of ABL1 inhibition on other highly glycolytic tumors. ...